Zhaowen Sun - Concepedia

Author

Zhaowen Sun

AbbVie (United States)

Also Known As

Z. Sun, Zhaowen Sun

Publications

559

Citations

H-Index

Concepts

All Affiliations

AbbVie (United States)Washington University in St. Louis Duke Medical Center Youngstown State University Aix-Marseille Université

About

Zhaowen Sun is an author at AbbVie (United States) specializing in cancer therapeutics, radiation oncology, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	1	1	16
2	Immunology	1	1	16
3	Pathology	1	1	16
4	Cancer Genetics	1	1	16
5	Cancer Therapeutics	1	1	16

Zhaowen Sun

Publications

534

Citations

H-Index

Page 1

	Year	Citations
Efficacy and Safety of Rovalpituzumab Tesirine Compared With Topotecan as Second-Line Therapy in DLL3-High SCLC: Results From the Phase 3 TAHOE Study Fiona Blackhall, Kevin Jao, Laurent Greillier, Journal of Thoracic Oncology	2021	239
Rovalpituzumab Tesirine as a Maintenance Therapy After First-Line Platinum-Based Chemotherapy in Patients With Extensive-Stage–SCLC: Results From the Phase 3 MERU Study Melissa L. Johnson, Zanete Zvirbule, Åslaug Helland, Journal of Thoracic Oncology	2021	147
Phase I Study of 2- or 3-Week Dosing of Telisotuzumab Vedotin, an Antibody–Drug Conjugate Targeting c-Met, Monotherapy in Patients with Advanced Non–Small Cell Lung Carcinoma D. Ross Camidge, Daniel Morgensztern, Rebecca S. Heist, Clinical Cancer Research	2021	74
Veliparib in combination with carboplatin/paclitaxel-based chemoradiotherapy in patients with stage III non-small cell lung cancer David Kozono, Thomas E. Stinchcombe, Joseph K. Salama, Lung Cancer	2021	23
The association between pulse pressure change and cognition in late life: Age and where you start matters Eric McDade, Zhaowen Sun, Ching‐Wen Lee, Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring	2016	20
Results of the phase 1b study of ABBV-399 (telisotuzumab vedotin; teliso-v) in combination with erlotinib in patients with c-Met+ non-small cell lung cancer by EGFR mutation status. D. Ross Camidge, Fabrice Barlési, Jonathan W. Goldman, Journal of Clinical Oncology Phase 1BAdvanced NsclcTelisotuzumab VedotinOncogenic AgentMedicine	2019	16
That’s Inappropriate! Social Norms in an Older Population-based Cohort Mary Ganguli, Zhaowen Sun, Eric McDade, Alzheimer Disease & Associated Disorders	2017	15

Page 1